Bioxytran Inc logo

BIXT - Bioxytran Inc Share Price

$0.18 0.0  0.0%

Last Trade - 23/02/21

Sector
Healthcare
Size
Micro Cap
Market Cap £12.6m
Enterprise Value £13.7m
Revenue £n/a
Position in Universe 6061st / 6715
Bullish
Bearish
Unlock BIXT Revenue
Momentum
Relative Strength (%)
1m -12.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -83.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.28 0.26 0.25 0.19 0.000 0.000 -100.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Bioxytran Inc revenues was not reported. Net loss increased40% to $1.7M. Higher net loss reflects Interest expenseincrease from $27K to $935K (expense), General andadministrative increase of 70% to $492K (expense). BasicEarnings per Share excluding Extraordinary Items decreasedfrom -$0.01 to -$0.02.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BIXT Revenue Unlock BIXT Revenue

Net Income

BIXT Net Income Unlock BIXT Revenue

Normalised EPS

BIXT Normalised EPS Unlock BIXT Revenue

PE Ratio Range

BIXT PE Ratio Range Unlock BIXT Revenue

Dividend Yield Range

BIXT Dividend Yield Range Unlock BIXT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIXT EPS Forecasts Unlock BIXT Revenue
Profile Summary

Bioxytran, Inc., formerly U.S. Rare Earth Minerals, Inc., is a developmental stage biotechnology company. The Company is focused on developing anti-necrosis drugs that treat an inadequate blood supply to an organ by delivering oxygen. Its oxygen delivery platform is being developed to treat victims with brain stroke trauma. Its pipeline includes BXT-25 and BXT-252. BXT-25 is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked and it is based on molecule reversing hypoxia (oxygen deficiency). BXT-252 is a resuscitative agent in a variety of wound healing applications. BXT-252 is designed to treat chronic wounds resulting from ischemia caused by occlusion of capillaries.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 9, 2008
Public Since March 22, 2007
No. of Shareholders: 1,005
No. of Employees: 2
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 97,187,673
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIXT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIXT
Upcoming Events for BIXT
Frequently Asked Questions for Bioxytran Inc
What is the Bioxytran Inc share price?

As of 23/02/21, shares in Bioxytran Inc are trading at $0.18, giving the company a market capitalisation of £12.6m. This share price information is delayed by 15 minutes.

How has the Bioxytran Inc share price performed this year?

Shares in Bioxytran Inc are currently trading at $0.18 and the price has moved by -40% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioxytran Inc price has moved by -54.21% over the past year.

What are the analyst and broker recommendations for Bioxytran Inc?

There are no analysts currently covering Bioxytran Inc.

When will Bioxytran Inc next release its financial results?

Bioxytran Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Bioxytran Inc dividend yield?

Bioxytran Inc does not currently pay a dividend.

Does Bioxytran Inc pay a dividend?

Bioxytran Inc does not currently pay a dividend.

When does Bioxytran Inc next pay dividends?

Bioxytran Inc does not currently pay a dividend.

How do I buy Bioxytran Inc shares?

To buy shares in Bioxytran Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bioxytran Inc?

Shares in Bioxytran Inc are currently trading at $0.18, giving the company a market capitalisation of £12.6m.

Where are Bioxytran Inc shares listed? Where are Bioxytran Inc shares listed?

Here are the trading details for Bioxytran Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: BIXT
What kind of share is Bioxytran Inc?

Based on an overall assessment of its quality, value and momentum, Bioxytran Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bioxytran Inc share price forecast 2021?

Shares in Bioxytran Inc are currently priced at $0.18. At that level they are trading at 1.37% discount to the analyst consensus target price of 0.00.

How can I tell whether the Bioxytran Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioxytran Inc. Over the past six months, the relative strength of its shares against the market has been 0.608k%. At the current price of $0.18, shares in Bioxytran Inc are trading at -25.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bioxytran Inc PE Ratio?

We were not able to find PE ratio data for Bioxytran Inc.

Who are the key directors of Bioxytran Inc?

Bioxytran Inc's management team is headed by:

David Platt - CHM
Ola Soderquist - CFO
Dale Conaway - IND
Anders Utter - IND
Alan Hoberman - IND
Henry Esber - IND
Who are the major shareholders of Bioxytran Inc?

Here are the top five shareholders of Bioxytran Inc based on the size of their shareholding:

Platt (David) Individual Investor
Percentage owned: 44.51% (43.3m shares)
Soderquist (Ola) Individual Investor
Percentage owned: 20.95% (20.4m shares)
Sheikh Michael M Individual Investor
Percentage owned: 9.29% (9.03m shares)
Offer (Binder) Individual Investor
Percentage owned: 9.18% (8.92m shares)
Hoberman (Alan M) Individual Investor
Percentage owned: 0.34% (331k shares)
Similar to BIXT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.